Re-evaluation of the Uplift Clinical Trial Using Age-Appropriate Spirometric Criteria

Area of Science:

• Pulmonary Medicine
• Clinical Trials
• Respiratory Research

Background:

• The UPLIFT clinical trial investigated tiotropium for COPD, enrolling patients with moderate-to-severe airflow obstruction based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
• The GOLD criteria used in UPLIFT may not be age-appropriate for the elderly COPD population studied.

Purpose of the Study:

• To determine if using Global Lung Function Initiative (GLI) criteria, which are more age-appropriate, alters the spirometric classification of UPLIFT participants.
• To assess if this reclassification impacts the observed mortality effect of tiotropium in COPD patients.

Main Methods:

• Spirometric classifications were cross-tabulated using both GLI and GOLD criteria.
• Modified intention-to-treat analyses compared tiotropium versus placebo for time to death over 4 years.
• Mortality effects were evaluated within strata of moderate and severe airflow obstruction defined by both GLI and GOLD criteria.

Main Results:

• GLI criteria reclassified a higher proportion of participants into moderate and severe airflow obstruction categories compared to GOLD criteria.
• Tiotropium showed statistically nonsignificant mortality benefits under both GLI and GOLD criteria overall.
• However, a significant mortality reduction (adjHR 0.53) was observed with tiotropium specifically in the GLI-defined moderate airflow obstruction group (P interaction = .007).

Conclusions:

• The Global Lung Function Initiative (GLI) criteria provide a more accurate spirometric classification for elderly COPD patients in the UPLIFT trial.
• Tiotropium demonstrated a significant mortality reduction in the GLI-defined moderate airflow obstruction group.
• This highlights potential underrepresentation of certain COPD severity groups in trials using older classification criteria, impacting treatment effect interpretation.